Miguel Martín

New England Journal of Medicine · 2005–2021

A researcher in the Science corpus: 14 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom Miguel Martín trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Jaka Demsar (in Evaluation & Benchmarks)

Papers from Miguel Martín's perspective

Ordered by how strongly the researchers Miguel Martín trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Statistical Comparisons of Classifiers over Multiple Data Sets
  2. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (JAMA Oncology)
  3. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer (npj Breast Cancer)
  4. Analysis of Incomplete Multivariate Data (Technometrics)
  5. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. (Journal of the National Cancer Institute)
  6. MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer (Clinical Cancer Research)
  7. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (Annals of Oncology)
  8. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (Annals of Oncology)
  9. Gene-expression signatures in breast cancer. (New England Journal of Medicine)
  10. Missing data: our view of the state of the art. (Psychological methods)

Their papers